Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Infection ; 47(2): 293-300, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30689161

ABSTRACT

Rituximab (RTX) has been classified as a drug associated with a high risk for hepatitis B virus (HBV) reactivation in HbsAg-negative/anti-HBc-positive patients. However, data on frequency of HBV reactivation are limited especially for RTX monotherapy. Several new recommendations for screening, monitoring and prophylactic antiviral treatment have been published recently. Here, we report the real-life experience in the management and reactivation rate of HbsAg-negative/anti-HBc-positive patients treated with RTX with or without chemotherapy from a large cohort and discuss our results in the light of updated recommendations.


Subject(s)
Antirheumatic Agents/therapeutic use , Hepatitis B virus/drug effects , Hepatitis B/drug therapy , Rituximab/therapeutic use , Virus Activation/drug effects , Adult , Aged , Cohort Studies , Drug Therapy, Combination , Female , Germany , Hepatitis B/virology , Hepatitis B Core Antigens/immunology , Hepatitis B Surface Antigens/immunology , Hepatitis B virus/physiology , Humans , Male , Middle Aged , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...